Skip to main content

BSI launches new cancer immunotherapy briefing

Cancer cell and lymphocyteEvery year, there are some 14 million new cases of cancer diagnosed worldwide, with approximately 350,000 cases occurring in the UK.  A new class of cancer therapies, collectively termed cancer immunotherapy, is designed to reactivate the body's immune response to cancer. Immunotherapy is showing exciting promise, with clear benefit now demonstrated in some cancers such as melanoma, lung, kidney and Hodgkin's lymphoma, but there is still much research to do.

The BSI has recently published a briefing to summarise what cancer immunotherapy is, the different types of cancer immunotherapy available, and the advantages and challenges of immunotherapy in treating one of the world’s greatest health challenges.

Read our cancer immunotherapy briefing